查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2005035

不可切除肝細胞癌市場：2026-2032年全球市場預測（依治療方法、作用機制、治療線、劑型、通路和最終用戶分類）

Unresectable Hepatocellular Carcinoma Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，不可切除肝細胞癌市值將達到 21.6 億美元，到 2026 年將成長至 24.3 億美元，到 2032 年將達到 53.5 億美元，年複合成長率為 13.79%。

主要市場統計數據
基準年 2025 21.6億美元
預計年份：2026年 24.3億美元
預測年份：2032年 53.5億美元
複合年成長率 (%) 13.79%

對目前不可切除肝細胞癌的狀況進行全面概述：重點關注臨床複雜性、未滿足的需求和不斷發展的護理標準。

無法手術切除的肝細胞癌在治療和商業方面都面臨著複雜的挑戰，涉及臨床緊迫性、不斷發展的科學知識和不斷變化的治療途徑。不適合手術切除的患者面臨不同的生物學特徵和合併症，這使得治療方法選擇更加複雜，需要採用涵蓋全身治療、局部治療和支持性治療的多方面綜合方法。臨床醫生和保險公司都必須仔細權衡新藥、聯合治療和不斷擴大的治療方案的療效、耐受性和資源利用。

治療創新、真實世界數據以及醫療保健服務體系的重新設計，是如何改變不可切除肝細胞癌的治療模式的？

不可切除肝細胞癌的治療格局正在經歷一場變革，這主要得益於機制和協作治療模式的突破性發現。免疫調節劑正在重新定義治療預期，並促使人們重新評估治療順序和聯合治療策略，而標靶激酶抑制劑則繼續為特定患者亞群提供有效的疾病控制。因此，多學科腫瘤諮詢擴大將全身免疫療法與局部和區域療法結合，以期獲得協同增效作用。

美國2025年實施的關稅對癌症治療的影響：供應鏈韌性評估、籌資策略調整與合約創新

美國關稅將於2025年全面實施，其累積影響正為癌症醫療保健領域的相關人員創造一個複雜的商業環境，並對供應鏈、籌資策略和成本結構產生連鎖反應。這些貿易措施促使人們重新評估原料藥和成品藥的採購方式，鼓勵製造商和經銷商實現供應商網路多元化，並評估區域性生產替代方案，以降低關稅相關成本波動帶來的風險。

將治療方法類型、作用機制、治療線、劑型、分銷管道和最終用戶環境與策略決策因素連結起來的實用細分見解。

細分市場趨勢揭示了不可切除肝細胞癌的臨床需求與商業性機會的交會點。根據治療方法類型，市場可分為聯合治療、局部/區域療法、支持性治療和全身療法，每種療法都需要獨特的開發和商業化策略，以反映臨床整合和臨床考量。例如，聯合治療方案需要製定策略規劃，涉及共同開發、安全管理以及與支付方的談判；而局部/區域療法則依賴手術網路和介入放射學框架。

美洲、歐洲、中東和非洲以及亞太地區的流行病學趨勢、法規結構和醫療保健基礎設施如何影響取得和部署策略？

不可切除肝細胞癌的區域趨勢反映了美洲、歐洲、中東和非洲以及亞太地區在流行病學、醫療基礎設施、監管管道和支付模式方面的差異，導致治療方案的採納曲線和戰略重點各不相同。在美洲，成熟的出版網路和先進的腫瘤中心促進了新型全身療法的快速臨床應用，而醫療技術評估和處方藥上市流程則影響著藥物的可及性和價格談判。學術機構通常主導聯合治療的臨床試驗和真實世界研究，這些研究對各國的臨床實踐模式產生影響。

為了加速不可切除肝細胞癌新治療方法的引入，各公司正在製定競爭策略，將轉化研究、夥伴關係模式和商業性執行相結合。

在不可切除肝細胞癌領域，領導企業憑藉其融合免疫腫瘤學、標靶治療和局部/區域治療技術的產品組合，以及策略聯盟和生命週期管理項目的支持，不斷開拓市場。主要企業正投資於聯合治療研發、生物標記發現和核准後證據生成，以實現產品差異化並展現其在臨床實踐中的價值。此外，製藥研發公司與介入器材製造商之間的合作也不斷湧現，旨在建構結合全身性治療和局部/區域介入的綜合治療方案。

為行業領導者提供實用建議，以協調臨床開發、市場進入和營運準備，從而最大限度地提高患者療效和商業性成功率。

產業領導者應採取協作方式，協調臨床開發、市場進入和交付準備工作，從而將治療創新與患者獲益聯繫起來。優先發展穩健的生物標記項目和適應性測試設計，能夠提高開發效率，並有助於在競爭激烈的治療領域實現差異化。儘早與支付方和衛生技術評估機構合作，並制定清晰的真實世界證據計劃，有助於消除准入障礙，並在不同的報銷環境下展現價值。

為了檢驗實際見解，我們採用高度透明的跨領域調查方法，結合專家訪談、臨床文獻整合以及供應鏈和政策分析。

本分析的調查方法融合了跨學科研究，以確保概念有效性、資料三角驗證和情境效度。主要研究包括與臨床專家、介入放射科醫生、藥劑師和政策相關人員進行結構化諮詢，以收集有關治療模式、操作限制和未滿足需求的實地見解。這些專家見解與對同行評審文獻的系統性回顧以及高品質的臨床實驗室數據相結合，從而建立了可靠的證據基礎。

策略整合強調治療創新、證據產生和實施準備的協調一致，以改善不可切除肝細胞癌的治療結果。

總之，不可切除的肝細胞癌處於快速治療創新與複雜遞送挑戰的交會點。免疫療法和標靶治療的進步為患者帶來顯著獲益，但要將這些成果轉化為廣泛的臨床影響，需要將研發策略與真實的臨床遞送環境進行精心匹配。相關人員必須優先考慮建立反映常規實踐的證據，建構穩健的供應鏈，並設計考慮當地實際情況的切實可行的准入策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：不可切除肝細胞癌市場：依治療方法

  • 聯合治療
  • 局部和區域療法
  • 支持性護理
  • 全身性治療

第9章：不可切除肝細胞癌市場：依作用機轉分類

  • 免疫查核點抑制劑
    • CTLA-4抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • mTOR抑制劑
  • 蛋白酪氨酸激酶抑制劑
    • 多激酶抑制劑
    • 選擇性激酶抑制劑

第10章：不可切除肝細胞癌市場：依治療方案分類

  • 第 1 行
  • 第二行
  • 第三行

第11章 不可切除肝細胞癌市場：依劑型分類

  • 注射
  • 口服

第12章 不可切除肝細胞癌市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 不可切除肝細胞癌市場：依最終用戶分類

  • 居家醫療設施
  • 醫院
  • 專科診所

第14章 不可切除肝細胞癌市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 不可切除肝細胞癌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 不可切除肝細胞癌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國不可切除肝細胞癌市場

第18章：中國不可切除肝細胞癌市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca AB
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • CStone Pharmaceuticals
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • Exelixis Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc.
  • Hengrui Medicine Co. Ltd.
  • Innovent Biologics Inc.
  • Ipsen SA
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Zai Lab Limited
Product Code: MRR-742BD5184A85

The Unresectable Hepatocellular Carcinoma Market was valued at USD 2.16 billion in 2025 and is projected to grow to USD 2.43 billion in 2026, with a CAGR of 13.79%, reaching USD 5.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.16 billion
Estimated Year [2026] USD 2.43 billion
Forecast Year [2032] USD 5.35 billion
CAGR (%) 13.79%

A comprehensive situational overview of unresectable hepatocellular carcinoma highlighting clinical complexity, unmet needs, and evolving standards of care

Unresectable hepatocellular carcinoma presents a complex therapeutic and commercial challenge that intersects clinical urgency, evolving scientific discoveries, and shifting care pathways. Patients who are ineligible for surgical resection face heterogeneous disease biology and comorbid conditions that complicate treatment choice, necessitating multifaceted approaches across systemic, locoregional, and supportive care domains. Clinicians and payers alike must weigh efficacy, tolerability, and resource utilization while navigating novel agents, combination regimens, and expanding lines of therapy.

Recent years have seen accelerating innovation in immuno-oncology and targeted therapies, yet access barriers, real-world safety considerations, and variable uptake across care settings continue to shape outcomes. In parallel, advancements in diagnostic imaging and biomarkers are refining patient selection, creating opportunities to better align therapeutic mechanisms with disease phenotypes. These developments demand an integrative perspective that combines clinical evidence, commercialization strategy, and health-system readiness.

This executive summary synthesizes current clinical paradigms, key shifts in therapeutic approaches, and actionable insights for stakeholders involved in drug development, market access, and clinical operations. It is designed to inform strategic decision-making by clarifying unmet needs, mapping treatment modalities to care settings, and highlighting the operational levers that can accelerate appropriate uptake and improve patient outcomes.

How therapeutic innovation, real-world evidence, and care delivery redesign are collectively reshaping treatment paradigms for unresectable hepatocellular carcinoma

The treatment landscape for unresectable hepatocellular carcinoma is undergoing transformative shifts driven by mechanistic breakthroughs and collaborative care models. Immune-modulating agents are redefining therapeutic expectations, prompting reassessment of sequencing and combination strategies, while targeted kinase inhibitors continue to provide meaningful disease control for selected patient subsets. As a result, multidisciplinary tumor boards increasingly integrate systemic immunotherapy with locoregional modalities to attain synergistic outcomes.

Concurrently, real-world evidence is emerging as a crucial complement to randomized data, enabling clinicians and payers to better understand tolerability, adherence, and outcomes across heterogeneous populations. This shift towards pragmatic evidence generation is influencing regulatory review pathways and reimbursement discussions, encouraging manufacturers to incorporate post-approval data strategies early in development planning. Additionally, the expansion of oral formulations and outpatient infusion capacity is altering care delivery models, facilitating decentralized treatment and greater patient convenience.

In synthesis, the current era is characterized by dynamic therapeutic innovation, a stronger emphasis on evidence that reflects routine practice, and operational changes that support broader access. Stakeholders who align clinical development with pragmatic evidence generation and delivery system readiness stand to translate scientific advances into sustained improvements in patient management.

Assessing the supply chain resilience, procurement adaptations, and contractual innovations prompted by US tariffs enacted in 2025 affecting oncology therapeutics

The cumulative impact of the United States tariffs introduced in 2025 has created a complex commercial environment for oncology stakeholders with implications for supply chains, procurement strategies, and cost structures. These trade measures have contributed to recalibration of sourcing practices for active pharmaceutical ingredients and finished products, prompting manufacturers and distributors to diversify supplier networks and evaluate regional manufacturing alternatives to mitigate exposure to tariff-related cost volatility.

In practical terms, some sponsors have accelerated nearshoring and contractual hedging to stabilize supply continuity and preserve pricing predictability for key oncology therapies. Health systems and hospital pharmacies are adapting procurement policies, placing greater emphasis on long-term supplier agreements and inventory optimization to avoid disruptions in treatment availability. Meanwhile, payers and policy stakeholders are increasingly scrutinizing the total cost of care, which has intensified conversations about value-based contracting and outcome-based payment models that can offset short-term tariff-driven cost pressures.

Overall, while tariffs have introduced commercial friction, they have also catalyzed supply chain resilience initiatives and more sophisticated contracting strategies. Organizations that proactively redesign sourcing and reimbursement approaches are better positioned to maintain continuity of care and ensure patient access to essential treatments despite macroeconomic headwinds.

Actionable segmentation insights connecting therapy types, mechanisms, lines of therapy, formulations, distribution channels, and end-user settings to strategic decision levers

Segment-level dynamics illuminate where clinical need intersects with commercial opportunity across unresectable hepatocellular carcinoma. Based on therapy type, the market spans combination therapy, locoregional therapy, supportive care, and systemic therapy, each requiring distinct development and commercialization approaches that reflect clinical integration and site-of-care considerations. Combination regimens, for example, demand strategic planning for co-development, safety management, and payer negotiation, whereas locoregional modalities rely on procedural networks and interventional radiology capacity.

Mechanism of action segmentation further refines strategic focus: immune checkpoint inhibitors, mTOR inhibitors, and tyrosine kinase inhibitors each have unique efficacy and safety profiles that influence positioning. Within immune checkpoint inhibitors, CTLA-4, PD-1, and PD-L1 agents show differential toxicity and biomarker relationships that inform combination choices and line-of-therapy sequencing. Tyrosine kinase inhibitors bifurcate into multi-kinase and selective kinase classes, with implications for off-target effects, dose optimization, and patient selection. These mechanistic distinctions should guide clinical trial design and post-marketing surveillance.

Line-of-therapy segmentation-first line, second line, and third line-dictates evidentiary thresholds and comparative benchmarks that sponsors must meet to secure formulary placement. Formulation preferences between injectable and oral options influence adherence, outpatient capacity, and logistics; oral agents may lower site-of-care burdens but require robust adherence support and pharmacovigilance. Distribution channel segmentation-hospital pharmacies, online pharmacies, and retail pharmacies-affects fulfillment, reimbursement pathways, and patient access pathways, requiring tailored market access strategies. Finally, end-user segmentation comprising home care settings, hospitals, and specialty clinics shapes educational outreach, training needs, and the infrastructure necessary for safe administration and monitoring. Collectively, these segmentation lenses should inform integrated development, access, and commercialization plans that match therapy attributes to real-world delivery models.

How regional epidemiology, regulatory frameworks, and healthcare infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific shape access and adoption strategies

Regional dynamics in unresectable hepatocellular carcinoma reflect differences in epidemiology, care infrastructure, regulatory pathways, and payer models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, producing varied adoption curves and strategic priorities. In the Americas, established referral networks and advanced oncology centers facilitate rapid clinical uptake of novel systemic therapies, while health technology assessment considerations and formulary processes shape access and pricing negotiations. Academic centers often lead combination trials and real-world studies that inform practice patterns nationwide.

Across Europe, the Middle East, and Africa, heterogeneity in regulatory frameworks and reimbursement systems requires nuanced approaches to evidence generation and market access. Several national systems emphasize comparative effectiveness and budget impact assessments, underscoring the importance of robust real-world and health economic data. In many markets within this region, constrained infrastructure for locoregional interventions and workforce limitations can affect the practical rollout of resource-intensive therapies, making implementation support and capacity building essential.

Asia-Pacific presents a diverse mix of high-capacity oncology centers and emerging markets with varying diagnostic and treatment capabilities. Rapidly growing clinical trial activity and manufacturing capacity in parts of the region influence global development timelines and supply strategies. However, affordability and out-of-pocket considerations remain central to uptake in several countries, requiring tiered pricing strategies and innovative access programs. Ultimately, region-specific engagement plans that align evidence generation with regulatory and reimbursement realities will be critical to achieving meaningful patient impact in each geography.

Competitive company strategies that combine translational research, partnership models, and commercial execution to accelerate adoption of new therapies for unresectable hepatocellular carcinoma

Key company dynamics in unresectable hepatocellular carcinoma are driven by portfolios that combine immuno-oncology, targeted agents, and locoregional technologies, supported by strategic alliances and lifecycle management programs. Leading organizations are investing in combination development, biomarker discovery, and post-approval evidence generation to differentiate products and demonstrate real-world value. Partnerships between pharmaceutical developers and interventional device manufacturers are also emerging to enable integrated therapy pathways that pair systemic agents with locoregional interventions.

Commercially, companies are optimizing go-to-market models by strengthening relationships with key oncology centers, developing nurse-led education initiatives, and deploying digital support tools to improve treatment adherence and adverse event management. Strategic imperatives include early payer engagement, development of health economic dossiers, and piloting value-based contracting where feasible. Additionally, manufacturing flexibility and regional supply strategies remain a competitive advantage, given recent pressures on global supply chains.

From an R&D perspective, firms prioritizing translational research to identify predictive biomarkers and mechanisms of resistance will be better positioned to design targeted combinations and sequence therapies effectively. Companies that combine clinical innovation with pragmatic commercial execution-aligning evidence generation to reimbursement needs and investing in provider education-are most likely to convert therapeutic advances into sustainable improvements in patient care.

Practical recommendations for industry leaders to align clinical development, market access, and operational readiness to maximize patient outcomes and commercial success

Industry leaders should adopt a coordinated approach that aligns clinical development, market access, and delivery system readiness to translate therapeutic innovation into patient benefit. Prioritizing robust biomarker programs and adaptive trial designs will increase the efficiency of development and support differentiation in crowded therapeutic classes. Early engagement with payers and health technology assessment bodies, combined with a clear real-world evidence plan, will pre-empt access barriers and support value demonstration across diverse reimbursement environments.

Operationally, companies should invest in supply chain diversification and manufacturing flexibility to mitigate tariff and geopolitical risks and ensure continuity of care. Equally important is the development of comprehensive patient support programs that address adherence, toxicity management, and financial navigation, particularly for oral and outpatient-administered therapies. Collaborative initiatives with academic centers, interventional specialists, and payers to pilot bundled care pathways can accelerate adoption of combination regimens and optimize outcomes.

Finally, leaders must cultivate cross-functional capabilities that integrate clinical strategy, market access, and field operations. Training programs for providers and pharmacists, scalable digital tools for remote monitoring, and outcome-focused contracting mechanisms will help align incentives and sustain long-term uptake. By executing on these recommendations, organizations can better position their portfolios to meet clinical needs while navigating evolving commercial and regulatory landscapes.

A transparent multidisciplinary research methodology combining expert interviews, clinical literature synthesis, and supply chain and policy analysis to validate actionable insights

The research methodology underpinning this analysis combines a multidisciplinary approach to ensure concept validity, data triangulation, and contextual relevance. Primary research included structured consultations with clinical experts, interventional radiologists, pharmacists, and policy stakeholders to capture frontline insights into treatment patterns, operational constraints, and unmet needs. These expert inputs were synthesized with a systematic review of peer-reviewed literature and high-quality clinical trial data to establish a robust evidentiary baseline.

Secondary research incorporated regulatory guidance, clinical guidelines, and publicly available health system reports to map region-specific pathways for approval and reimbursement. Supply chain and commercial impact assessments drew on industry sources and contract analyses to identify stress points and mitigation strategies. All findings were validated through iterative expert review and cross-checked against real-world practice patterns where available.

The methodology emphasizes transparency in assumptions, the use of diverse data types to reduce bias, and a focus on actionable intelligence. Limitations include variability in reporting across health systems and rapidly evolving clinical data that may alter practice patterns; therefore, continuous surveillance and periodic updates are recommended to maintain relevance for strategic decision-making.

Strategic synthesis underscoring the convergence of therapeutic innovation, evidence generation, and implementation readiness required to improve outcomes in unresectable hepatocellular carcinoma

In conclusion, unresectable hepatocellular carcinoma sits at the intersection of rapid therapeutic innovation and complex delivery challenges. Advances in immune-based therapies and targeted agents are creating new opportunities for meaningful patient benefit, yet converting those gains into widespread clinical impact requires careful alignment of development strategies with real-world delivery ecosystems. Stakeholders must prioritize evidence generation that reflects routine practice, build resilient supply chains, and design pragmatic access approaches that account for regional nuances.

Moreover, segmentation-informed strategies that link therapy attributes to formulation, distribution channels, and end-user settings will enable more precise commercialization and implementation plans. Companies that integrate biomarker-driven development, robust post-marketing evidence, and payer-centric value demonstration will be best positioned to navigate the evolving landscape. Finally, collaborative engagement among industry, clinicians, and health systems will be essential to translate scientific progress into durable improvements in patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Unresectable Hepatocellular Carcinoma Market, by Therapy Type

  • 8.1. Combination Therapy
  • 8.2. Locoregional Therapy
  • 8.3. Supportive Care
  • 8.4. Systemic Therapy

9. Unresectable Hepatocellular Carcinoma Market, by Mechanism Of Action

  • 9.1. Immune Checkpoint Inhibitors
    • 9.1.1. Ctla-4 Inhibitors
    • 9.1.2. Pd-1 Inhibitors
    • 9.1.3. Pd-L1 Inhibitors
  • 9.2. Mtor Inhibitors
  • 9.3. Tyrosine Kinase Inhibitors
    • 9.3.1. Multi Kinase Inhibitors
    • 9.3.2. Selective Kinase Inhibitors

10. Unresectable Hepatocellular Carcinoma Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Second Line
  • 10.3. Third Line

11. Unresectable Hepatocellular Carcinoma Market, by Formulation

  • 11.1. Injectable
  • 11.2. Oral

12. Unresectable Hepatocellular Carcinoma Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Unresectable Hepatocellular Carcinoma Market, by End User

  • 13.1. Home Care Settings
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. Unresectable Hepatocellular Carcinoma Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Unresectable Hepatocellular Carcinoma Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Unresectable Hepatocellular Carcinoma Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Unresectable Hepatocellular Carcinoma Market

18. China Unresectable Hepatocellular Carcinoma Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. AstraZeneca AB
  • 19.8. AstraZeneca PLC
  • 19.9. Bayer AG
  • 19.10. BeiGene Ltd.
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Celgene Corporation
  • 19.13. CStone Pharmaceuticals
  • 19.14. Eisai Co. Ltd.
  • 19.15. Eli Lilly and Company
  • 19.16. Exelixis Inc.
  • 19.17. F. Hoffmann-La Roche Ltd
  • 19.18. Gilead Sciences Inc.
  • 19.19. Hengrui Medicine Co. Ltd.
  • 19.20. Innovent Biologics Inc.
  • 19.21. Ipsen S.A.
  • 19.22. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • 19.23. Merck & Co. Inc.
  • 19.24. Novartis AG
  • 19.25. Pfizer Inc.
  • 19.26. Roche Holding AG
  • 19.27. Sanofi S.A.
  • 19.28. Zai Lab Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LOCOREGIONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUPPORTIVE CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUPPORTIVE CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUPPORTIVE CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SYSTEMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MTOR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MTOR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MULTI KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MULTI KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MULTI KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SELECTIVE KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SELECTIVE KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SELECTIVE KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 165. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 167. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 169. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GCC UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 192. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 194. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. G7 UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. NATO UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA UNRESECTABLE HEPATOCELLULAR CARCINOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)